CB Therapeutics: Producing Rare Cannabinoid & Psychedelic Molecules at Scale
November 10th, 2020
App, Exclusive, Psychedelics, Top Story
The cannabis industry has evolved from the legalization of dried cannabis to an increasingly detailed understanding of individual cannabinoids. While THC and CBD are the two most common, researchers are increasingly interested in CBC, THCV and other rare cannabinoids that could have specific and desirable effects on certain medical indications.
The problem is that these cannabinoids can’t be efficiently produced at scale since they are contained in such small quantities in the plant. These scalability issues are mirrored in the psychedelics industry where plants like mescaline take a decade or more to reach maturity, making it challenging to produce enough to meet growing demand.
Let’s take a look at two key issues facing the cannabis and psychedelics industry, why biosynthesis could provide a solution and how CB Therapeutics Inc. plans to provide a solution.
Lack of Scalability
Mescaline has been used for centuries by Mexican Indians and Native Americans in the Southwest for certain religious ceremonies and rituals. With the decriminalization of psychedelics in several U.S. cities, demand for the cacti has soared and overharvesting has become a problem since the plants take decades to regenerate and product fruit.
While these problems could imperil local religious traditions that rely on the plant, the concerning trend points to a wider problem facing the industry—a lack of scalability. Cultivating and harvesting psychedelic plants is not a very efficient way to create psychedelic compounds at scale to meet demand from both consumers and researchers.
Chemical synthesis is often touted as a solution to the problem since it involves creating compounds in a lab rather than extracting them from a plant. The problem is that chemical synthesis is a time-consuming process that generates a lot of waste, which means that—while it’s more scalable than cultivation—it’s still not ideal over the long run.
Quality Control Issues
Quality control is another important issue facing the cannabis and psychedelics industries. Without standardized active ingredient profiles, it’s impossible for researchers to accurately determine how a therapy impacts patients. That’s why the vast majority of consumer prescriptions come in tablets with very exacting levels of active pharmaceutical ingredients.
Not surprisingly, different plants have different levels of active ingredients within them that depend on everything from the environment to the extraction method. Cannabis plants, for example, have differing levels of cannabinoids and terpenes depending on their genetics, growing environment and a variety of other factors.
There may also be quality control issues that stem from the cultivation process itself. For instance, mold, heavy metals and other contaminants have frequently made it into consumer goods within the cannabis industry. These contaminants often come from cultivation processes that use pesticides and other things to prevent infestations.
Biosyn to the Rescue
The combination of scalability and quality control issues have made cannabis and psychedelic molecules very expensive to produce. Unfortunately, the lack of high-quality molecules has created a bottleneck for researchers of novel therapies, as well as a shortage in therapeutics that have already been approved.
CB Therapeutics Inc. believes that biosynthesis provides the ideal solution to these problems. Using yeast- and bacteria-based production techniques with simple feedstocks, the company’s cellular production processes can produce a broad range of phytochemicals faster, more sustainably, at greater yields and with higher purity, consistency and efficiency.
For example, the company recently announced that its downstream processing allowed for 99.6% pure CBC—a rare cannabinoid molecule found in trace quantities in cannabis and help. These techniques promise to drive down the cost of purification in parallel with increasing purity to over 99%—a major breakthrough for the industry.
CB Therapeutics Inc. is uniquely positioned to supply the cannabis and psychedelic research communities with rare molecules at scale. In addition to enabling research, the company hopes that these therapeutics eventually come to market and create large-scale demand for its unique cellular production technology—delivering significant long-term value for shareholders.
For more information, visit the company’s website or download their investor presentation.
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.